Adtalem (ATGE) Q4 2025: Walden Enrollment Up 15% as Healthcare Education Demand Accelerates
Adtalem’s “growth with purpose” strategy delivered a standout year, marked by double-digit enrollment gains and margin expansion, with Walden University leading at 15% enrollment growth in Q4. Strategic investments in student-facing technology, targeted marketing, and employer partnerships are driving share gains across segments, positioning Adtalem to capitalize on secular healthcare workforce shortages. Management’s guidance signals continued confidence, with new capacity investments and alternative student financing solutions set to support further growth in FY26.
Summary
- Walden’s Enrollment Surges: Robust execution drove 15% Q4 enrollment growth at Walden, outpacing industry trends.
- Strategic Capital Deployment: Increased investments in technology and employer partnerships are expanding Adtalem’s competitive moat.
- Regulatory Adaptation: Management’s proactive response to loan caps and alternative financing reduces risk to student demand.
Performance Analysis
Adtalem delivered a strong finish to FY25, with revenue up double digits and margin expansion reflecting both operational discipline and targeted investment in growth levers. Walden University was the clear outperformer, posting 16.6% revenue growth and 15% higher enrollment, driven by demand in both nursing and social and behavioral health programs. Chamberlain University also contributed, with 10.3% revenue growth and a 5.8% enrollment increase, marking its tenth consecutive quarter of growth despite a planned step-up in investment that compressed margins in the near term. The medical and veterinary segment saw modest 4.7% revenue growth and 1% enrollment expansion, with Ross Vet operating near capacity and early signs of momentum at AUC and Ross Med.
Margin performance was a highlight, with consolidated adjusted EBITDA margin up 190 basis points for the year to 25.7%, as operational leverage from enrollment gains outpaced incremental investment in marketing and technology. Free cash flow generation remained robust at $283 million, supporting $211 million in share repurchases and a further reduction in leverage. The balance sheet ended the year with $200 million in cash and a 0.8x net leverage ratio, providing ample flexibility for continued capital deployment.
- Walden Margin Expansion: Adjusted EBITDA margin at Walden rose 260 basis points to 28.9% as scale and efficiency offset higher brand and student support spend.
- Chamberlain Margin Compression: Planned growth investments drove a 390 basis point margin decline to 24.4%, but management signals this is a deliberate tradeoff to capture future growth.
- Capital Allocation Discipline: The completion of a $300 million buyback and launch of a new $150 million authorization reflect confidence in long-term value creation.
Enrollment momentum and operational leverage are translating into durable earnings power, with guidance for FY26 reflecting confidence in continued top-line and margin expansion.
Executive Commentary
"Our growth with purpose strategy delivered outstanding financial results and meaningful student outcomes, exceeding our plan and marking a clear inflection point in our growth trajectory. We've re-engineered our institutional footprint around a unified model that unlocks operating leverage and accelerates profitability."
Steve Beard, Chairman and Chief Executive Officer
"We've fundamentally transformed the organization through operational excellence, built a strong foundation, and created a durable growth engine. Our trajectory has increased the level of operating cash flow, affording us the ability to be disciplined capital allocators."
Bob Phelan, Chief Financial Officer
Strategic Positioning
1. Multi-Segment Healthcare Focus
Adtalem’s business model is centered on career-aligned healthcare education, spanning nursing, medicine, veterinary, and social behavioral sciences. The company’s scale—serving over 94,000 students and graduating 29,000 professionals this year—positions it as a critical pipeline for the U.S. healthcare workforce, with proprietary institutions supplying 17% of new registered nurses nationally.
2. Brand and Marketing Innovation
Management’s continued evolution of brand strategy and segmentation has driven improved student awareness, conversion, and share gains. Localized marketing at Chamberlain and program-level campaigns at Walden have increased inquiry-to-enrollment efficiency, while partnerships like the new SSM Health alliance provide differentiated employment pathways for students.
3. Technology and Student Outcomes
Investment in AI-powered learning tools and student-facing technology is improving retention and persistence rates, supporting enrollment growth and lowering acquisition costs. These enhancements are core to Adtalem’s “growth with purpose” framework, aligning academic outcomes with employer needs and regulatory expectations.
4. Proactive Regulatory and Financing Response
With new federal loan caps and the elimination of Grad Plus, Adtalem announced a letter of intent with Sallie Mae to create alternative financing options, aiming to ensure uninterrupted access for students. Management views recent legislation as reducing long-term regulatory risk and leveling the playing field across higher education providers.
5. Capacity Expansion and New Program Opportunities
Adtalem is investing to expand capacity and explore new program launches, particularly in allied health, to address secular workforce shortages and demographic trends. Management sees substantial room to grow within existing verticals before pursuing major portfolio diversification.
Key Considerations
Adtalem’s Q4 performance underscores the sustainability of its growth model and the strategic levers driving its outperformance versus peers:
Key Considerations:
- Enrollment Growth as a Leading Indicator: Double-digit gains at Walden and sustained momentum at Chamberlain suggest continued share capture and resilience to macro headwinds.
- Margin Expansion Supported by Operational Leverage: Scale benefits are outpacing incremental investment, driving improved profitability even as the company invests for future growth.
- Capital Return and Balance Sheet Strength: Aggressive share repurchases and low leverage highlight management’s confidence and financial flexibility.
- Regulatory Navigation and Financing Innovation: Proactive adaptation to policy changes reduces risk to student demand and positions Adtalem as a stable partner for both students and employers.
Risks
Regulatory changes remain a material risk, particularly around federal student loan policy, though management’s partnership with Sallie Mae and grandfathering provisions mitigate near-term disruption. Execution risk exists in scaling new capacity and maintaining high student outcomes as competition intensifies. Macroeconomic or demographic shifts impacting healthcare employment could also affect demand, though secular shortages provide a cushion.
Forward Outlook
For Q1 2026, Adtalem guided to:
- Revenue growth and EPS expansion weighted toward the first half, with a one-week academic shift at Walden boosting Q2 at the expense of Q3.
- Continued investment in marketing and technology, with incremental spend pacing through the year based on opportunity and seasonality.
For full-year 2026, management raised guidance:
- Revenue of $1.90 to $1.94 billion
- Adjusted EPS of $7.60 to $7.90
Management highlighted several factors that support the outlook:
- Secular healthcare workforce shortages driving persistent demand
- Expanded partnerships and new program launches to unlock incremental growth
Takeaways
Adtalem’s Q4 2025 results reinforce its position as a leading healthcare educator with a scalable, resilient model.
- Enrollment Growth Outpaces Peers: Sustained double-digit enrollment gains at Walden and Chamberlain point to share gains and a robust demand environment.
- Strategic Investment Drives Moat: Ongoing investments in technology, marketing, and employer partnerships are compounding operational leverage and student outcomes.
- Watch for Capacity and Program Expansion: The pace and success of new capacity additions and alternative financing solutions will be critical to sustaining above-market growth in FY26 and beyond.
Conclusion
Adtalem exits FY25 with clear momentum, underpinned by strong execution, disciplined capital allocation, and strategic adaptation to regulatory change. Investors should monitor the pace of capacity expansion, the impact of alternative student financing, and continued margin improvement as key levers for sustained outperformance.
Industry Read-Through
Adtalem’s results provide a bullish read-through for the for-profit healthcare education sector, highlighting the durability of demand for career-aligned programs and the importance of employer partnerships in driving enrollment and outcomes. Institutions with scale, brand strength, and the ability to adapt to regulatory change are best positioned to capture share as traditional higher education faces increased scrutiny. The company’s proactive approach to financing innovation and capacity expansion sets a template for peers navigating similar policy and demographic challenges.